1. Introduction {#sec1-medicines-06-00047}
===============

Despite the impressive breakthroughs in the treatment of malaria \[[@B1-medicines-06-00047]\], it remains a life-threatening disease. Southeast Asia and sub-Saharan Africa account for the vast majority of the estimated 219 million malaria cases reported worldwide, leading to 435,000 deaths \[[@B2-medicines-06-00047]\]. More than 90% of malaria cases and deaths occur in Africa, of which more than 70% are children under five years of age \[[@B2-medicines-06-00047]\]. The prospect of resistance to current drugs appears inevitable and paints a bleak picture indeed \[[@B3-medicines-06-00047]\]. Although the reasons for this dire situation are complex, there is undoubtedly a need for the continued search for and development of new antimalarial drugs. Natural products have historically offered some of the most effective antimalarial drugs \[[@B4-medicines-06-00047]\]. In a previous study, we reported on the antiplasmodial activity of natural products isolated from the South African brown seaweed, *Sargassum incisifolium,* against a chloroquine sensitive strain of *Plasmodium falciparum* (D10) \[[@B5-medicines-06-00047]\]. *S. incisifolium* is relatively abundant along the South African coastline and produces sargahydroquinoic acid (**1**) as the major metabolite. The accessibility of **1** thus provided an opportunity to explore the structure activity relationships of analogs of this natural product. Herein we report on the antiplasmodial activity of semi-synthetic analogs of sargahydroquinoic acid (**1**) ([Figure 1](#medicines-06-00047-f001){ref-type="fig"}).

2. Materials and Methods {#sec2-medicines-06-00047}
========================

2.1. General Experimental {#sec2dot1-medicines-06-00047}
-------------------------

All solvents were of chromatographic grade (Merck, Darmstadt, Germany) and used without further purification. Column chromatography was performed on silica gel (40--63 μm particle size) from Merck, Darmstadt, Germany. Normal Phase HPLC was carried out using a Whatman Partisil 10 semi-preparative column (Sigma-Aldrich, Schnelldorf, Germany) (10 mm × 500 mm, 10 μm), while a Phenomenex Luna C~18~ column (Sigma-Aldrich, Schnelldorf, Germany, 10 mm × 250 mm, 10 μm) was used for reversed phase HPLC. NMR spectra were recorded on Bruker Avance 400 and 600 MHz spectrometers (Bruker Biospin, Rheinstetten, Germany) and referenced to residual undeuterated CDCl~3~ solvent signals (δ~H~ 7.26 ppm and δ~C~ 77.0 ppm). UV spectra were measured on a Perkin Elmer Lambda 25 UV/Vis spectrometer (Perkin-Elmer, Norwalk, CT, USA) while FT-IR data was obtained using a Perkin Elmer Spectrum 100 FT-IR spectrometer (Perkin-Elmer, Norwalk, CT, USA). High resolution electrospray ionization mass spectroscopy (HR-ESIMS) spectra were obtained on a Waters Synapt G2 mass spectrometer (Waters Corporation, Milford, MA, USA) at 20 V.

2.2. Extraction and Isolation of Natural Products {#sec2dot2-medicines-06-00047}
-------------------------------------------------

Specimens of *Sargassum incisifolium* were collected from Port Alfred (collection code PA071b) on the south east coast of South Africa on 21 September 2007 and stored at −20 °C. The samples were authenticated by comparison with voucher specimens from previous studies \[[@B5-medicines-06-00047]\]. Voucher specimens are stored at the School of Pharmacy, University of the Western Cape.

The following isolation protocol is representative and was repeated several times in order to generate sufficient quantities of **1** for synthetic modification. The frozen alga (38.77 g, extracted dry weight) was allowed to thaw at room temperature after which it was soaked in methanol for one hour. The methanol was removed and the alga extracted three times with MeOH-CH~2~Cl~2~ (1:2) at 40 °C for 30 min. Extracts were pooled and separated into aqueous and organic phases by the addition of distilled water. Concentration of the organic phase under reduced pressure gave a dark green residue (3.87 g). A portion of the organic fraction (1.09 g) was fractionated by step-gradient elution on a silica gel column (10 g) using solvents of increasing polarity (*n*-hexane-EtOAc) to give seven fractions as follows: Fr A (H-E, 10:0, 8.6 mg), Fr B (H-E, 9:1, 27 mg), Fr C (H-E, 8:2, 132 mg), Fr D (H-E, 6:4, 218 mg), Fr E (H-E, 4:6, 65 mg), Fr F (H-E, 2:8, 9.7 mg) and Fr G (H-E, 0:10, 50 mg) followed by MeOH-EtOAc (1:1), Fr 7H (238 mg). Fraction B (19 mg) was further purified by silica gel column chromatography using a mobile phase of *n*-hexane-EtOAc (9:1) to give 1.7 mg of sargaquinal (**9**). Fraction C (40 mg) was purified by normal phase HPLC using *n*-hexane-EtOAc as mobile phase (8:2) to give 15 mg of sargaquinoic acid (**3**). Fraction D (20 mg) was purified by reversed phase HPLC using MeOH-H~2~O phase (90:10) as the mobile phase to give sargahydroquinoic acid (**1**) (6.8 mg) and sargachromenol (**7**) (2.4 mg), respectively. The isolation of compounds **1**, **3**, **7** and **9** is summarised in [Scheme S1](#app1-medicines-06-00047){ref-type="app"} and their structures were confirmed by spectroscopic methods, which were in agreement with literature data ([Table S1](#app1-medicines-06-00047){ref-type="app"}) \[[@B5-medicines-06-00047]\]. The NMR spectra for compounds **1** ([Figures S1 and S2](#app1-medicines-06-00047){ref-type="app"}), **3** ([Figures S3 and S4](#app1-medicines-06-00047){ref-type="app"}), **7** ([Figures S5 and S6](#app1-medicines-06-00047){ref-type="app"}) and **9** ([Figures S7 and S8](#app1-medicines-06-00047){ref-type="app"}) are presented in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

2.3. Sargaquinoic Acid (**3**) and Sarganaphthoquinoic Acid (**10**) {#sec2dot3-medicines-06-00047}
--------------------------------------------------------------------

To a solution of **1** (154.0 mg, 0.36 mmol) in a mixture of CHCl~3~ (8 mL) and MeOH (7 mL) was added Ag~2~O (100 mg, 0.43 mmol). The reaction mixture was stirred at room temperature for 24 h, after which the resulting suspension was filtered through diatomaceous earth and concentrated under reduced pressure. The crude product was filtered through a plug of charcoal (*n*-hexane-EtOAc, 4:6) to give a yellow mixture of compounds which was separated by silica gel column chromatography (*n*-hexane-EtOAc, 7:3) to give sargaquinoic acid (**3**) (80 mg, 70%) and compound **10** (9.8 mg, 6%) as light yellow oils. NMR spectra for compound **10** ([Figures S9--S14](#app1-medicines-06-00047){ref-type="app"}) can be found in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

Sarganaphthoquinonoic acid (**10**): IR (film) ν~max~ (cm^−1^): 1600, 1663, 2850, 2924; ^1^H and ^13^C NMR data see [Table 1](#medicines-06-00047-t001){ref-type="table"}; HRESIMS *m/z* 419.2222 \[M-H\] (calcd. for C~27~H~35~O~3~, 419.2221)

2.4. Sargaquinoic Acid Methyl ester (**5**) {#sec2dot4-medicines-06-00047}
-------------------------------------------

To a solution of **1** (122.4 mg, 0.29 mmol) dissolved in 2 mL acetone, was added K~2~CO~3~ (207.4 mg, 1.50 mmol) in 5 mL acetone and dimethylsulphate (250 µL, 2.63 mmol). The mixture was heated at 40 °C for 8 h followed by stirring at room temperature for 16 h. The reaction mixture was filtered, concentrated under reduced pressure and separated by silica gel column chromatography (*n*-hexane- EtOAc, 8:2) to give the methyl ester of **1**, which, upon exposure to air was completely oxidized to **5**. NMR spectra for compound **5** ([Figures S15--S16](#app1-medicines-06-00047){ref-type="app"}) can be found in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

Yellow oil, ^1^H NMR (400 MHz, CDCl~3~) δ 6.52 (1H, s, H-3), 6.44 (1H, s, H-5), 5.83 (1H, t, *J* = 7.0 Hz, H-10'), 5.10 (3H, m, H-2', H-6', H-14'), 3.71 (3H, s, OMe), 3.11 (2H, d, *J* = 6.8 Hz, H-1'), 2.49 (2H, m, H-9'), 2.22 (2H, m, H-12'), 2.05 (2H, m, H-4') 2.03-2.05 (6H, m, H-5', H-8', H-13'), 1.65 (6H, s, H-7, H-19'), 1.61 (3H, s, H-20'), 1.58 (3H, s, H-16'), 1.55 (3H, s, H-17'); 188.0 (C-1, C-4), 168.4 (C-18'), 148.4 (C-6), 145.8 (C-2), 142.1 (C-10'), 140.0 (C-3') 134.8 (C-7') 133.1 (C-3, C-15'), 132.1 (C-5), 131.4 (C-11'), 124.4 (C-6'), 123.5 (C-14'), 118.0 (C-2'), 51.0 (OMe), 39.8 (C-4'), 39.1 (C-8'), 34.7 (C-12'), 28.0 (C-9'), 27.8 (C13'), 27.5 (C-1'), 26.4 (C-5'), 25.6 (C-16'), 17.6 (C-17'), 16.1 (C-7), 15.9 (C-19'); HRESIMS *m/z* 437.2710 \[M-H\] (calcd. for C~28~H~37~O~4~, 437.2692).

2.5. Diacetyl Sargahydroquinoic Acid (**2**) {#sec2dot5-medicines-06-00047}
--------------------------------------------

To sargahydroquinoic acid (**1**) (110.0 mg, 0.26 mmol) was added acetic anhydride (3 mL, 31.8 mmol) and pyridine (2 mL, 24.8 mmol). The reaction mixture was stirred at room temperature for 30 h. The crude product was acidified with 1 M HCl (10 mL) and extracted with EtOAc (5 mL × 3). The organic layer was collected and concentrated under reduced pressure to give a crude product which was further purified by silica gel column chromatography (*n*-hexane:EtOAc, 7:3) to give compound **2** (12.8 mg, 12%) as a yellow oil. The structure of compound **2** was confirmed by spectroscopic methods, which were in agreement with literature data \[[@B6-medicines-06-00047],[@B7-medicines-06-00047]\]. NMR spectra for compound **2** ([Figures S17 and S18](#app1-medicines-06-00047){ref-type="app"}) can be found in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

2.6. Sargaquinol (**6**) and Sargachromendiol (**8**) {#sec2dot6-medicines-06-00047}
-----------------------------------------------------

To a solution of sargahydroquinoic acid (**1**) (140.7 mg, 0.33 mmol) dissolved in anhydrous THF (5 mL), was added LiAlH~4~ (0.104 g, 2.74 mmol). The reaction mixture was stirred at room temperature, under a nitrogen atmosphere for 1.25 h. The reaction was quenched with a few drops of EtOAc, concentrated and partitioned between EtOAc (10 mL^−2^) and H~2~O (5 mL). The organic layer was concentrated under reduced pressure to give a crude product which was purified by silica gel chromatography (*n*-hexane:EtOAc, 8:2) to give sargaquinol (**6**) (12.2 mg, 30%) and the alcohol derivative of sargachromenol (**8**) (2.8 mg, 3.5%). The structure of compound **6** was confirmed by spectroscopic methods, which were in agreement with literature data ([Table S1](#app1-medicines-06-00047){ref-type="app"}) \[[@B7-medicines-06-00047]\]. NMR spectra for compounds **6** ([Figures S19 and S20](#app1-medicines-06-00047){ref-type="app"}) and **8** ([Figures S21 and S22](#app1-medicines-06-00047){ref-type="app"}) can be found in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

Sargaquinol (**6**) yellow oil; ^1^H NMR (400 MHz, CDCl~3~) δ 6.54 (s, 1H) (H-3), 6.46 (s, 1H) (H-5), 5.15 (dd, *J* = 21.0, 13.2 Hz) (H- 2', 6', 14'), 4.11 (s) (H-18'), 3.63 (t, *J* = 6.5 Hz) (H-10'), 3.12 (d, *J* = 7.1 Hz) (H-1'), 2.12 (s) (H-5', 9', 13'), 2.05 (s) (H-4', 8'), 1.67 (s) (H- 7, 16'), 1.60 (s) (H-19', 20'), 1.57 (s) (H-17'). ^13^C NMR (100 MHz, CDCl~3~) δ 188.0 (C-1), 187.97 (C-4), 148.5 (C-6), 145.9 (C-2), 139.7 (C-3'), 135.0 (C-7'), 133.1 (C-3), 131,2 (C-11'), 132.24 (C-5), 133.7 (C-15'), 124.7 (C-6'), 124.2 (C-14'), 118.1 (C-2'), 71.8 (C-18'), 62.8 (C-10'), 39.8 (C-4'), 39.5 (C-8'), 35.2 (C-12'), 27.1 (C-13'),27.5 (C-1'), 26.2 (C-5'), 26.3 (C-9'), 25.6 (C-16'), 17.7 (C-7), 16.11 (C-17'), 16.07 (C-19'), 16.0 (C-20').

Sargachromendiol (**8**) yellow oil; ^1^H NMR (400 MHz, CDCl~3~) δ 6.47 (d, *J* = 2.4 Hz) (H-5), 6.32 (d, *J* = 2.5 Hz) (H-2), 6.26 (s) (H-2'), 5.98 (t, *J* = 7.2 Hz) (H-9'), 5.57 (d, *J* = 9.8 Hz) (H-3'), 5.12 (dt, *J* = 19.0, 6.4 Hz) (H-5', 14'), 2.59 (q, *J* = 7.3 Hz (H-8'), 2.27 (t, *J* = 7.4 Hz), 2.13 (s) (H-12'), 2.09--2.04 (m) (H-4', 7'), 1.68 (s) (H-8), 1.58 (d, *J* = 3.5 Hz) (H-17', 19'), 1.36 (s) (20'); ^13^C NMR (100 MHz, CDCl~3~) δ 148.6 (C-5), 145.0 (C-10'), 144.8 (C-8), 134.7 (C-7'), 131.8 (C-15'), 130.6 (C-11'), 126.3 (C-3), 124.7 (C-6'), 124.1 (C-1'), 122.9 (C-14'), 121.3 (C-2), 117.0 (C-4), 110.3 (C-6), 77.8 (C-3'), 60.3 (C-18'), 40.7 (C-4'), 39.8 (C-8'), 35.1 (C-12'), 35.3 (C-12'), 27.0 (C-9'), 26.1 (C-13'), 25.9 (C-20'), 25.7 (C-16'), 22.6 (C-5'), 17.7 (17'), 15.9 (C-7), 15.5 (C-19').

2.7. Z-sargaquinal (**4**) {#sec2dot7-medicines-06-00047}
--------------------------

To a solution of sargaquinol (**6**) (37.2 mg, 0.09 mmol) dissolved in anhydrous CH~2~Cl~2~ (8 mL), Dess-Martin Periodinane (107 mg, 0.26 mmol) was added. The reaction mixture was stirred at room temperature for 2 h after which it was quenched with CH~2~Cl~2~ (10 mL) and de-ionized water (10 mL). The organic phase was separated and washed with saturated solutions of NaHCO~3~ (10 mL × 3) and Na~2~S~2~O~3~ (10 mL × 3), dried over anhydrous Na~2~SO~4~ and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (*n*-hexane:EtOAc, 8:2) to give compound **4** (42%, 14.9 mg), as a yellow oil. The structure of compound **4** was confirmed by spectroscopic methods, which were in agreement with literature data ([Table S1](#app1-medicines-06-00047){ref-type="app"}) \[[@B7-medicines-06-00047]\]. NMR spectra for compound **4** ([Figures S23--S24](#app1-medicines-06-00047){ref-type="app"}) can be found in the [Supplementary Materials](#app1-medicines-06-00047){ref-type="app"}.

2.8. Antiplasmodial Assays {#sec2dot8-medicines-06-00047}
--------------------------

All compounds were tested in triplicate against the chloroquine-resistant Gambian FCR-3 strain of *P. falciparum*. The in vitro erythrocytic stage of the parasite was maintained using the method outlined by Trager and Jensen \[[@B8-medicines-06-00047]\]. The antimalarial activity of the compounds was determined using the tritiated hypoxanthine incorporation assay using a 0.5% parasitaemia and 1% haematocrit \[[@B9-medicines-06-00047]\]. All assays were carried out using untreated parasites and uninfected red blood cells as controls. The concentration that inhibited 50% parasite growth (IC~50~ value) was determined from the log sigmoid dose response curve using GraphPad Prism. Quinine was used as the reference antiplasmodial agent. The selectivity index for the compounds was determined from the ratio of cytotoxicity IC~50~ to antimalarial IC~50~.

2.9. Cytotoxicity Assay {#sec2dot9-medicines-06-00047}
-----------------------

All compounds were tested in triplicate against MDA-MB-231 breast carcinoma cells, which were purchased from the ATCC (Catalogue number HTB-26, Manassas, VA, USA). The cytotoxicity of the compounds was determined using the WST-1 assay method (Roche). The cells were treated with a range of concentrations of the test compounds or vehicle control (DMSO). Cells treated with DMSO were considered to represent 100% viability and the viability of cells at each dose was represented relative to this value. The concentration resulting in a decrease of cell viability to 50% was calculated from the linear portion of the dose response curve.

3. Results and Discussion {#sec3-medicines-06-00047}
=========================

3.1. Isolation and Synthetic Modification of Sargahydroquinoic Acid Derivatives {#sec3dot1-medicines-06-00047}
-------------------------------------------------------------------------------

Sargahydroquinoic acid (**1**) is the major component of the CH~2~Cl~2~-MeOH extract of *Sargassum incisifolium* and has also been reported from several other *Sargassum* spp. \[[@B5-medicines-06-00047],[@B6-medicines-06-00047],[@B7-medicines-06-00047]\]. This compound slowly converts to sargaquinoic acid (**3**) and sargachromenol (**7**) on storage of the seaweed, the extract and during purification. Specimens of *S. incisifolium* (PA071b) were collected from Port Alfred on the south eastern coast of South Africa and extracted with CH~2~Cl~2~-MeOH. The crude extract was first fractionated by silica gel column chromatography, followed by normal or reversed phase HPLC to give compounds **1**, **3**, **7** and **9**. The identities of all isolated compounds were confirmed by comparison of their NMR spectroscopic data ([Table S1](#app1-medicines-06-00047){ref-type="app"}) to literature values \[[@B5-medicines-06-00047]\]. The above protocol yielded sufficient quantities of **1** to perform structural modifications and biological assays.

Sargaquinoic acid (**3**) is normally isolated from fresh seaweed in relatively small quantities; however, it can be produced more efficiently by the oxidation of **1 \[[@B7-medicines-06-00047],[@B10-medicines-06-00047]\]**. Thus, treatment of **1** with Ag~2~O gave **3** in moderate to good yields. Interestingly, although this conversion is facile, we consistently observed a series of unusual peaks between δ~H~ 7 and 8 in the ^1^H NMR spectrum of the crude reaction product. The compound (**10**) responsible for these peaks was isolated and its structure was elucidated by NMR spectroscopy and mass spectrometry.

The HRESIMS spectrum of compound **10** showed a molecular ion peak at *m/z* 419.2222 \[M-H\] which corresponds to a molecular formula of C~27~H~31~O~4~. Characteristic deshielded methine resonances at δ~H~ 8.00 (d, *J* = 7.9), δ 7.98 (s) and δ 7.51 (d, *J* = 7.9) were evident in its ^1^H NMR spectrum. In addition, one of the aromatic singlets had shifted downfield from δ~H~ 6.46 in **3** to δ~H~ 6.81 in **10**. Data from the ^13^C NMR spectrum of compound **10** revealed no change in the number of carbon atoms when compared to the starting material (**1**). It revealed the presence of two quinone carbonyls signals at (δ~C~ 185.4 and δ 185.4) and a carboxylic acid moiety (δ~C~ 171.9). In addition, the DEPT-135 NMR spectrum indicated the loss of one methyl signal (δ~C~ 16.1, C-20') and a methylene signal (δ~C~ 27.5, C-1') when compared to **3**, together with the appearance of two additional olefinic methine signals at δ~C~ 126.7 (C-1') and 125.9 (C-20'). HMBC correlations ([Figure 2](#medicines-06-00047-f002){ref-type="fig"}) from the doublet at δ~H~ 8.00 (H-1') to carbon signals at δ~C~ 126.7 (C-1') and δ~C~ 133.8 (C-2'); the methine signal at δ~H~ 7.51 (H-2') to the carbon signal at δ~C~ 125.9 (C-20') and from δ~H~ 7.86 (H-20') to carbon signals at δ~C~ 36.2 (C-4') and δ~C~ 185.4 (C-4), allowed for the assignment of the naphthoquinone moiety. All other spectroscopic data are consistent with a polyprenyl side chain with a 6'*E*,10'*Z*-double bond geometry (as in **3**). We assigned the name sarganaphthoquinoic acid to this new compound. A related compound, chabrolonaphthoquinone, had previously been reported from the Taiwanese soft coral, *Nephthea chabrolii* \[[@B11-medicines-06-00047]\]. The main differences between the two compounds are the methyl substituent at C-6 and the 10-double bond geometry in compound **10**.

The direct conversion of prenylated hydroquinones to naphthoquinones is uncommon and presents a novel approach to the synthesis of this important group of compounds. To the best of our knowledge there is only a single report describing the formation of a naphthoquinone as a side-product in the synthesis of chromenes from prenylated quinones \[[@B12-medicines-06-00047]\]. Naphthoquinones are typically synthesized by Diels-Alder reactions between *p*-benzoquinones and dienes or by the prenylation of halogenated naphthoquinone moieties \[[@B13-medicines-06-00047],[@B14-medicines-06-00047],[@B15-medicines-06-00047]\]. Compound **10** is proposed to form via tautomerism and oxidation of the intermediate quinone (**3**) followed by 6πelectrocyclization and further oxidation ([Scheme 1](#medicines-06-00047-sch001){ref-type="scheme"}).

In order to establish preliminary structure-antiplasmodial activity relationships for this series of sargahydroquinoic acid derivatives, we focused our attention on modification of the carboxylic acid and quinone moieties. Acetylation of **1** with acetic anhydride/pyridine gave the diacetate (**2**), while its reduction with lithium aluminium hydride gave a mixture of sargaquinol (**6**) and sargachromendiol (**8**). The facile conversion of the hydroquinone to a mixture of the quinone and chromene on exposure to air is often seen in this series of compounds \[[@B6-medicines-06-00047],[@B7-medicines-06-00047]\]. Spectroscopic evidence for the identity of alcohols **6** and **8** were provided by the disappearance of the ^13^C NMR signal due to the carboxylic acid group at δ~C~ 172 ppm and the appearance of an oxymethylene carbon signal at δ~C~ 60.3 ppm in both compounds.

Mild oxidation of **6** with Dess-Martin periodinane, gave 10*Z*-sargaquinal (**4**). The structures of aldehydes **4** and **9** were confirmed by comparison of their spectroscopic data with literature values \[[@B5-medicines-06-00047],[@B7-medicines-06-00047]\]. A comparison of the ^1^H NMR spectra of the natural and semi-synthetic aldehydes revealed differences in chemical shifts of both proton and carbon atoms associated with the aldehyde group. The ^1^H and ^13^C NMR spectra of the semi-synthetic aldehyde (**4**) showed signals at δ~H~ 10.1 and δ~C~ 190.9 ppm compared to δ~H~ 9.55 and δ~C~ 205.4 ppm in the natural aldehyde (**9**). ^1^H-^1^H NOESY correlations in both compounds confirmed the difference in the geometry of the Δ^10^ double bond with the semi-synthetic aldehyde (**4**) bearing a 10*Z*-geometry and the natural aldehyde (**9**) a 10*E*-geometry. The formation of 2'*E*,6'*E*,10'*Z*-sargaquinal (**4**) from 2'*E*,6'*E*,10'*Z*-sargahydroquinoic acid (**1**) has been reported in the literature \[[@B7-medicines-06-00047]\]. However, this is the first report of its ^13^C and 2D NMR data.

Interestingly, methylation of **1** with dimethylsulphate/potassium carbonate did not produce the dimethyl ether, but instead produced sargaquinoic acid methyl ester (**5**). This was confirmed by the appearance of an additional methyl signal at δ~C~ 51.0 and an upfield shift of the C-18' carbonyl signal from δ~C~ 172 to δ 168.4 ppm in the ^13^C NMR spectrum of **5** ([Table S1](#app1-medicines-06-00047){ref-type="app"}).

3.2. Biological Assays {#sec3dot2-medicines-06-00047}
----------------------

The ten sargahydroquinoic acid derivatives were assessed for both antiplasmodial and cytotoxic activity against the chloroquine-resistant Gambian FCR-3 strain of *P. falciparum* and MDA-MB-231 breast cells, respectively ([Table 2](#medicines-06-00047-t002){ref-type="table"}). All compounds showed moderate to good antiplasmodial activity. However, the most promising compound in this series is the naphthoquinone **10** which not only revealed good antiplasmodial activity (IC~50~ 5.4 μM), but also very low cytotoxicity (IC~50~ 2410 μM), resulting in a high selectivity index of 443. Sargaquinoic acid (**3**) also shows promising antiplasmodial activity (IC~50~ 10.8 μM), but is slightly more toxic (IC~50~ 658 μM) than **10**. It appears that the carboxylic acid in the prenyl side chain is important for activity since both aldehydes (**4**) and (**9**) and the alcohol (**6**) showed decreased antiplasmodial activity. The quinone/naphthoquinone scaffold is present in several antimalarial natural products and drugs \[[@B16-medicines-06-00047]\]. It is therefore likely that the mode of action of the compounds reported here is related to this important pharmacophore \[[@B16-medicines-06-00047],[@B17-medicines-06-00047],[@B18-medicines-06-00047],[@B19-medicines-06-00047],[@B20-medicines-06-00047]\].

4. Conclusions {#sec4-medicines-06-00047}
==============

In this study we isolated the relatively abundant antiplasmodial natural product, sargahydroquinoic acid (**1**) and converted it to several analogs which were evaluated for antiplasmodial and cytotoxic activity. The serendipitous formation of sarganaphthoquinoic acid (**10**) gave a compound with good antiplasmodial activity while being almost non-toxic. Due to the small number of compounds no clear structure activity relationships can be established, however it appears that the presence of a quinone and carboxylic acid are important for selective activity against *P. falciparum*. Further studies are warranted to explore the mode of action of these compounds and to further improve on its antiplasmodial activity.
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Click here for additional data file.
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###### 

NMR spectroscopic data for sarganaphthoquinoic aicd (**10**) (600 and 125 MHz, CDCl~3~).

  Carbon Number   δ~C~    Type    δ~H~, mult, *J* (Hz)   COSY                HMBC
  --------------- ------- ------- ---------------------- ------------------- ------------------
  1               185.4   C       \-                                         
  2               130.2   C       \-                                         
  3               132.2   C       \-                                         
  4               185.4   C       \-                                         
  5               136.0   CH      6.81, s                H-7                 
  6               149.0   C       \-                                         
  7               16.4    CH~3~   2.18, s,               H-5                 C-6, C-5
  1'              126.7   CH      8.00, d, 7.9           H-2'                C-2, C-1
  2'              133.8   CH      7.51, d, 7.9           H-4', H-20'         C-1, C-20'
  3'              148.2   C       \-                                         
  4'              36.2    CH~2~   2.77, t, 7.6           H-5'                C-5', C-3'
  5'              29.1    CH~2~   2.36, m                H-4', H-6'          C-4', C-6', C-7'
  6'              123.2   CH      5.17, m                                    
  7'              136.0   C       \-                                         
  8'              39.0    CH~2~   2.08, m                H-9'                C-6'
  9'              28.2    CH~2~   2.57, m                H-10'               C-8', C-10'
  10'             145.0   CH      5.96, t, 7.3           H-9'                C-8'
  11'             130.6   C       \-                                         
  12'             27.8    CH~2~   2.26, m                H-13', H-14' (lr)   C-13', C-14'
  13'             28.2    CH~2~   2.11, m                H-14'               C-15', C-11'
  14'             123.4   CH      5.17, t, 7.0           H-13', H-14' (lr)   
  15'             132.3   C       \-                                         
  16'             25.6    CH~3~   1.68, s                H-14' (lr)          C-15', C-14'
  17'             17.7    CH~3~   1.59, s                H-14' (lr)          C-16'
  18'             171.9   C       \-                                         
  19'             15.9    CH~3~   1.58, s                H-6'                C-6'
  20'             125.9   CH      7.86, s                H-4'                C-4', C-4

COSY: ^1^H-^1^H Correlation spectroscopy; HMBC: ^1^H-^13^C Heteronuclear multiple-bond correlation spectroscopy.
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###### 

Bioassay results for compounds **1**--**10**.

  Compound                                    IC~50~ (μM)   Selectivity Index          
  ------------------------------------------- ------------- ------------------- ------ ------
  Sargahydroquinoic acid (**1**)              15.2          38.6                70     1.8
  Sargahydroquinoic acid di-acetate (**2**)   \-            84.3                286    3.4
  Sargaquinoic acid (**3**)                   12.0          10.8                658    60.9
  10*Z*-sargaquinal (**4**)                   \-            72.6                211    2.9
  Sargaquinoic acid methyl ester (**5**)      \-            8.2                 70     8.6
  Sargaquinol (**6**)                         \-            93.1                99     1.1
  Sargachromenol (**7**)                      \-            114.8               56     0.5
  Sargachromendiol (**8**)                    \-            34.2                187    5.5
  10*E*-sargaquinal (**9**)                   2.0           104.4               69     0.7
  Sarganaphthoquinone (**10**)                \-            5.4                 2410   443
  Quinine                                                   0.17                \-     \-

^1^ From reference \[[@B5-medicines-06-00047]\].
